PMID- 10349111
OWN - NLM
STAT- MEDLINE
DCOM- 19990819
LR  - 20131121
IS  - 0025-7680 (Print)
IS  - 0025-7680 (Linking)
VI  - 59
IP  - 1
DP  - 1999
TI  - [Bone marrow transplantation in chronic myeloid leukemia].
PG  - 1-10
AB  - Chronic Myelogenous Leukemia (CML) is an oncohematological disease characterized 
      by a clonal proliferation concerning the primitive hematopoietic cell. A typical 
      cytogenetic alteration known as Philadelphia Chromosome (Ph1), a 9:22 chromosomic 
      translocation which produces a hybrid gene BCR/ABL, is present in 95% of the 
      patients. Nineteen CML patients (9 female and 10 male) underwent Bone Marrow 
      Transplantation (BMT). Median age was 32 years (range 9 to 47); 15 of them were 
      in chronic phase (CP), and 4 in accelerated phase (AP). At diagnosis, all 
      patients were Ph1+, BCR/ABL+. The conditioning regimen consisted of busulphan and 
      cyclophosphamide while patients in AP received etoposide as well. Seventeen 
      patients received cyclosporine A, methotrexate and methylprednisone as 
      prophylaxis for Graft Versus Host Disease (GVHD) while 2 patients received only 
      the first two drugs. The 9.22 translocation was determined by means of RT-PCT 
      technique using the primers NB1+, Abl3, B2A, CA3 and A2. The sensitivity of the 
      method was 1 x 10(-6). Among the 19 patients who entered the protocol, 14 are 
      alive and in clinical, hematological and cytogenetic remission (Ph1-) and 3 
      patients died due to acute GVHD, 1 due to graft failure and 1 due to Hemolytic 
      Uremic Syndrome. Of the 4 transplanted patients in AP, 3 are alive and in 
      complete remission. The patients had a 74% survival, with a median follow-up of 
      655 days. Complete hematopoietic chimerism was demonstrated in 16 patients, with 
      the study of 3 loci, D1S80, APO B and D17S30. No relationship was found between 
      post BMT hybrid BCR/ABL (RT.PCR) persistence and disease relapse; the presence of 
      acute and/or chronic GVHD did not influence the BCR/ABL positivity. In our 
      experience, BMT has proved to be the only therapeutic alternative for CML with 
      complete clinical, hematological and cytogenetic remission and a mean survival of 
      74%, comparable to the international experience.
FAU - Milone, J H
AU  - Milone JH
AD  - Instituto de Transplante de Medula Osea (ITMO), Fundacion Dr. Jose M. Mainetti, 
      Gonnet, La Plata.
FAU - Bordone, J
AU  - Bordone J
FAU - Etchegoyen, O
AU  - Etchegoyen O
FAU - Napal, J
AU  - Napal J
FAU - Prates, M V
AU  - Prates MV
FAU - Morales, V H
AU  - Morales VH
LA  - spa
PT  - English Abstract
PT  - Journal Article
TT  - Transplante de medula osea en leucemia mieloide cronica.
PL  - Argentina
TA  - Medicina (B Aires)
JT  - Medicina
JID - 0204271
RN  - EC 2.7.10.2 (Fusion Proteins, bcr-abl)
SB  - IM
MH  - Actuarial Analysis
MH  - Adult
MH  - *Bone Marrow Transplantation
MH  - Child
MH  - Female
MH  - Follow-Up Studies
MH  - Fusion Proteins, bcr-abl/genetics
MH  - Graft vs Host Disease/drug therapy/prevention & control
MH  - Humans
MH  - Leukemia, Myelogenous, Chronic, BCR-ABL Positive/*genetics/*therapy
MH  - Male
MH  - Microsatellite Repeats/genetics
MH  - Middle Aged
MH  - Neoplasm, Residual
MH  - Remission Induction
MH  - Sensitivity and Specificity
EDAT- 1999/06/01 00:00
MHDA- 1999/06/01 00:01
CRDT- 1999/06/01 00:00
PHST- 1999/06/01 00:00 [pubmed]
PHST- 1999/06/01 00:01 [medline]
PHST- 1999/06/01 00:00 [entrez]
PST - ppublish
SO  - Medicina (B Aires). 1999;59(1):1-10.